• In January 2023, Cryoport announced a collaboration with Syneos Health aimed at advancing cell and gene therapies. This partnership seeks to provide an integrated solution for the cell and gene industry by combining Cryoport's IntegriCell platform with Syneos Health's supply chain services.

• In June 2023, SkyCell, a leading manufacturer of temperature-controlled containers for the pharmaceutical sector, partnered with Marken to offer advanced shipping solutions for pharmaceutical products in clinical trials. Marken will leverage SkyCell containers to transport critical and temperature-sensitive drugs effectively.

• In October 2023, Parexel International Corporation and Partex established a strategic alliance to leverage artificial intelligence (AI) in accelerating global drug discovery and development. This collaboration focuses on addressing challenges in investigational therapies by prioritizing assets with the highest likelihood of clinical success, enabling biopharmaceutical companies to optimize their resources for maximum patient benefit.

• In June 2022, Catalent, Inc. announced plans to expand its primary packaging capabilities by installing an advanced blister packaging line at its clinical supply facility in Shiga, Japan, complementing its existing automated bottling line.

• In July 2021, the company revealed its intention to inaugurate a new clinical trial supplies depot in China, aimed at facilitating prompt access to medications and supplies for patients and clinical sites.

In this report, the Global Clinical Trial Supply and Logistics Market has been segmented by Service, Phase, Therapeutic Area, End User and Geography.

Global Clinical Trial Supply and Logistics Market, Segmentation by Service

The Global Clinical Trial Supply and Logistics Market has been segmented by Service into Logistics & distribution, Storage & retention, Packaging, labeling, and blinding, Manufacturing, Comparator sourcing, and Others.

Logistics & Distribution
Logistics and distribution dominate the clinical trial supply and logistics market with a 30% share. This segment is essential for managing the global movement of clinical supplies, including temperature-sensitive biologics and time-critical materials. As decentralized and multinational trials grow, sponsors demand real-time tracking, customs compliance, and efficient last-mile delivery solutions.

Storage & Retention
Storage and retention services contribute about 15% of the market. These offerings ensure safe and compliant storage of investigational drugs and samples across trial phases. Cold chain warehousing, retention of trial materials for audits, and inventory control are key components in maintaining regulatory readiness.

Packaging, Labeling, and Blinding
With approximately 20% market share, this segment plays a vital role in preserving trial integrity and patient safety. Services include clinical packaging design, multi-language regulatory labeling, and blinding/unblinding of investigational products to maintain double-blind study protocols.

Manufacturing
Manufacturing services represent nearly 18% of the market. These include GMP-compliant production of trial materials such as APIs, IMPs, comparators, and placebos. The growing complexity of trial designs and increasing demand for biologics have raised the bar for quality and scalability in clinical manufacturing.

Comparator Sourcing
Comparator sourcing holds around 10% of the global market. Sponsors require precise and timely access to branded reference drugs for comparative trials. Vendors must navigate procurement, import/export regulations, and expiry management to ensure trial continuity.

Others
Other services, comprising about 7% of the market, include returns handling, destruction of unused medications, quality control audits, and trial supply strategy consulting. These value-added services support compliance, cost-efficiency, and process optimization across the clinical trial supply chain.

Global Clinical Trial Supply and Logistics Market, Segmentation by Phase

The Global Clinical Trial Supply and Logistics Market has been segmented by Phase into Phase I, Phase II, Phase III, and Phase IV.

Phase I
Phase I clinical trials represent about 15% of the global clinical trial supply and logistics market. These studies, typically involving a small group of healthy volunteers, focus on safety and dosage exploration. Supply needs include small batch manufacturing, expedited delivery, and adaptive packaging for rapid protocol changes.

Phase II
Phase II trials make up nearly 25% of the market. These trials test the drug’s effectiveness and safety in a targeted patient population. Logistics at this stage require larger-scale packaging, precise labeling, temperature-controlled shipments, and mid-volume global distribution.

Phase III
Phase III dominates with a market share of approximately 45%. These late-stage trials are conducted across multiple countries and involve thousands of participants. Clinical trial supply chains at this phase must support GMP-compliant manufacturing, multi-language labeling, bulk distribution, and strict regulatory documentation.

Phase IV
Phase IV trials contribute around 15%. Also known as post-marketing surveillance studies, they assess long-term safety and real-world effectiveness. These trials require durable logistics frameworks to support ongoing sample collection, product returns, and real-time adherence monitoring.

Global Clinical Trial Supply and Logistics Market, Segmentation by Therapeutic Area

The Global Clinical Trial Supply and Logistics Market has been segmented by Therapeutic Area into Oncology, Cardiovascular Diseases, Respiratory Diseases, CNS And Mental Disorders, and Others.

Oncology
Oncology dominates the clinical trial supply and logistics market, contributing nearly 40% of the total share. With a surge in cancer-related trials involving biologics, immunotherapies, and personalized medicine, sponsors require scalable supply chains with robust cold chain infrastructure, multi-site delivery coordination, and strict compliance management.

Cardiovascular Diseases
Cardiovascular disease trials represent approximately 20% of the market. These trials often include large, diverse patient groups and require synchronized global logistics, demand forecasting, and efficient inventory replenishment systems. The increasing focus on chronic conditions like heart failure and hypertension drives steady growth in this segment.

Respiratory Diseases
Respiratory disease trials make up about 12% of the market, driven by the need for rapid trial setup and delivery of critical treatments. The COVID-19 pandemic significantly elevated the segment's importance, emphasizing the role of flexible, real-time logistics and emergency cold chain delivery networks.

CNS and Mental Disorders
CNS and mental disorder studies hold around 18% of the market. These trials often involve sensitive populations and extended study durations. Supply logistics must ensure precise blinding, patient-specific dosing kits, and long-term packaging integrity to support consistent data collection.

Others
Other therapeutic areas, contributing roughly 10%, include clinical studies in dermatology, infectious diseases, rare genetic conditions, and endocrine disorders. These trials typically require highly adaptable supply models, niche sourcing, and strict adherence to region-specific regulations.

Global Clinical Trial Supply and Logistics Market, Segmentation by End User

The Global Clinical Trial Supply and Logistics Market has been segmented by End User into Pharmaceuticals, Biologicals, and Medical Device.

Pharmaceuticals
Pharmaceutical companies dominate the clinical trial supply and logistics market with a share of about 50%. These sponsors lead large-scale global trials that require complex logistics coordination, from investigational product manufacturing and clinical packaging to bulk labeling and international distribution. Increased drug development activity and regulatory rigor are expanding supply demands across all phases.

Biologicals
Biologicals represent approximately 35% of the market, driven by the surge in biologics and cell & gene therapy trials. These trials require strict temperature controls, cryogenic storage, and rapid global transport. Biopharma companies increasingly partner with specialized logistics providers to ensure quality, stability, and compliance for temperature-sensitive biologics.

Medical Device
The medical device sector accounts for nearly 15% of the market. Clinical trials in this category involve diagnostic tools, implantable devices, and wearable technologies. Logistics for medical device trials require tailored packaging, traceability systems, multi-country regulatory documentation, and often include return/reuse management for devices in long-term studies.

Global Clinical Trial Supply and Logistics Market, Segmentation by Geography

In this report, the Global Clinical Trial Supply and Logistics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Global Clinical Trial Supply and Logistics Market Share (%), by Geographical Region, 2024

North America
North America dominates the global clinical trial supply and logistics market with a share of around 40%. The region is home to major pharmaceutical companies and CROs, supported by advanced cold chain logistics, regulatory clarity from the FDA, and a high volume of Phase II and III trials. The U.S. and Canada are key hubs for global clinical trial coordination and supply chain execution.

Europe
Europe holds approximately 25% of the market. The implementation of the EU Clinical Trials Regulation (CTR) has harmonized trial operations, making the region more efficient for cross-border logistics and trial execution. Countries such as Germany, France, and the UK provide mature infrastructure for storage, labeling, and comparator sourcing.

Asia Pacific
Asia Pacific accounts for roughly 20% of the market. This region is rapidly emerging as a clinical trial hotspot due to its large patient population, low trial costs, and expanding pharmaceutical manufacturing base. Nations like China, India, and Japan are experiencing a surge in trial activity and require increasingly sophisticated supply logistics.

Middle East & Africa
Middle East & Africa contribute close to 8% of global share. Investments in healthcare infrastructure, growing interest from multinational sponsors, and an expanding network of trial sites in the UAE, Saudi Arabia, and South Africa are driving growth in this under-penetrated but promising region.

Latin America
Latin America represents about 7% of the market. With increasing regulatory streamlining and growing investments in clinical research infrastructure, countries such as Brazil, Mexico, and Argentina are becoming attractive destinations for late-phase trials, creating consistent demand for regional supply and logistics services.

This report provides an in depth analysis of various factors that impact the dynamics of Global Clinical Trial Supply and Logistics Market. These factors include; Market Drivers, Restraints, and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers:

• Increasing Clinical Trial Activities
• Rising Outsourcing Trends
• Globalization of Clinical Trials
• Advancements in Biopharmaceutical Research

• Focus on Patient-Centricity - The increasing focus on patient-centricity is a key driver shaping the growth of the global clinical trial supply and logistics market. As sponsors and contract research organizations (CROs) prioritize patient convenience and engagement, there is growing adoption of decentralized and hybrid clinical trial models. These models require flexible, responsive, and patient-friendly supply chains that can support direct-to-patient (DTP) deliveries, home-based participation, and personalized dosing schedules—drastically transforming traditional logistics workflows.

  To enhance patient recruitment, retention, and compliance, clinical trial supply chains must now deliver real-time tracking, temperature-sensitive logistics, and customized packaging solutions. This demand for greater responsiveness and adaptability is prompting investment in advanced technologies such as digital tracking systems, AI-driven forecasting, and remote inventory management. As patient-centricity continues to guide clinical trial design, the market for innovative and agile logistics solutions is expected to experience sustained global expansion.

Restraints:

• Logistical Challenges
• Supply Chain Disruptions
• Quality Assurance and Compliance
• Socioeconomic Factors

• Data Security and Privacy Concerns - Data security and privacy concerns are significant restraints impacting the global clinical trial supply and logistics market. As clinical trials become more digitized and decentralized, vast amounts of sensitive patient data are transmitted across multiple platforms, including electronic data capture (EDC) systems, remote monitoring tools, and direct-to-patient delivery networks. This increasing digital footprint heightens the risk of cybersecurity breaches, unauthorized access, and non-compliance with privacy regulations such as HIPAA and GDPR.

  Ensuring the confidentiality and integrity of patient information requires robust IT infrastructure, secure data encryption, and stringent access controls—factors that can significantly increase operational complexity and cost. Additionally, any breach or mishandling of data can result in regulatory penalties, reputational damage, and trial delays, deterring sponsors from fully embracing digital supply chain models. Addressing these concerns through advanced cybersecurity solutions and regulatory compliance frameworks is essential to unlocking the full potential of technology-enabled clinical logistics.

Opportunities:

• Digital Transformation
• Decentralized Clinical Trials
• Precision Medicine and Personalized Therapies
• Focus on Sustainability

• Customized Solutions for Rare Diseases - The demand for customized solutions for rare diseases presents a valuable opportunity in the global clinical trial supply and logistics market. Rare disease trials often involve small, geographically dispersed patient populations, making conventional supply chain models inefficient. These trials require highly specialized logistics support, including tailored packaging, precise dosing, cold chain management, and direct-to-patient delivery to ensure the safe and timely administration of investigational products.

  With growing investment in orphan drug development and regulatory incentives such as fast-track approvals and market exclusivity, pharmaceutical companies are increasingly conducting rare disease trials. This shift is driving demand for agile, patient-specific logistics strategies capable of supporting low-volume, high-value shipments with minimal lead times. Logistics providers offering scalable, flexible, and compliance-ready solutions are well-positioned to capitalize on this emerging segment.

  In addition, rare disease trials often require adaptive supply chain planning due to frequent protocol amendments and limited manufacturing output. This complexity creates opportunities for specialized service providers to deliver customized forecasting, real-time inventory management, and decentralized distribution models. As personalized medicine gains traction, the ability to support these nuanced trial designs will become a key differentiator in the evolving clinical logistics landscape.

Key players in Global Clinical Trial Supply and Logistics Market include:

• Thermo Fisher Scientific (Patheon)
• Catalent, Inc.
• Parexel International (MA) Corporation
• Almac Group
• Marken
• Piramal Pharma Solutions
• UDG Healthcare
• DHL
• FedEx
• Movianto
• Packaging Coordinators Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis